Navigation Links
TAXIS Pharmaceuticals licenses novel antimicrobial technology from Rutgers and UMDNJ
Date:10/13/2009

TAXIS Pharmaceuticals, Inc. (TAXIS), Rutgers, The State University of New Jersey, and the University of Medicine and Dentistry of New Jersey (UMDNJ) have entered into an exclusive licensing agreement for worldwide rights to develop and commercialize a novel antimicrobial technology addressing multidrug-resistant (MDR) bacterial infections. The alarming rise in the number of multidrug-resistant (MDR) bacterial pathogens that have emerged and spread in recent years has dramatically reduced the utility of the current arsenal of antibiotics. Two such MDR pathogens in particular have been recognized as major threats to global public health, methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). TAXIS is in the process of identifying and validating lead drug candidates that target MRSA and VRE with efficacies that are superior to current standards of therapeutic care.

"The compounds under investigation have great potential to treat a broad-spectrum of emerging, drug-resistant pathogens that represent large and growing public health and biodefense threats", said Gregory Mario, TAXIS' Chief Executive Officer. "We are excited to develop these further and move them closer to the clinic." The novel antimicrobial technology was discovered at the universities by Professors Daniel S. Pilch, Ph.D. (Department of Pharmacology, UMDNJ-Robert Wood Johnson Medical School) and Edmond J. LaVoie, Ph.D. (Department of Medicinal Chemistry, Rutgers University-Ernest Mario School of Pharmacy).


'/>"/>

Contact: Gregory G. Mario
GMario@TAXISPharma.com
609-240-8463
Rutgers University
Source:Eurekalert

Page: 1

Related biology news :

1. InVivo and CEVEC pharmaceuticals sign license agreement regarding the use of human CAP-T Technology for production of recombinant proteins
2. Anadys Pharmaceuticals to Present at the Roth OC Growth Stock Conference
3. Singulex Teams With Wyeth Pharmaceuticals to Translate Pre-Clinical Biomarker Research Into Clinical Study Design
4. NMR researchers unlock hydrogens secrets to spot polymorphism in pharmaceuticals
5. Researchers develop liquid crystal pharmaceuticals to fight cancer and other diseases
6. Bacteria from sponges make new pharmaceuticals
7. MSU licenses plant oil enhancement technology to BASF Plant Science
8. UGA licenses technology to make fuel from dead forests and agricultural waste
9. UGA licenses new Bermuda grass that thrives in sun and shade
10. UGA licenses invention that kills food-borne pathogens in minutes
11. Ocera Therapeutics licenses novel treatment for acute hepatic encephalopathy from UCLB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/13/2015)... JOSE, Calif. , July 13, 2015 /PRNewswire/ ... leading developer of human interface solutions, today announced ... generation touch and display driver integration (TDDI) product ... is the first to combine Synaptics , ... with proven display driver technology developed in the ...
(Date:7/9/2015)... Research and Markets( ... "Biometrics for Banking; Market & Technology Analysis, ... their offering. The adoption for banking ... and the forecast is that by 2020 it ... involved in delivering biometric systems to the banking ...
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
Breaking Biology News(10 mins):Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... the most important resource for the world's population, and their ... discussion during the seminar 'A new look on the ocean' ... primary focus of the seminar will be on utilisation and ... and society. Friedhelm Schröder and Wilhelm Petersen of the GKSS ...
... it's a daunting task to find a smoking gun ... to say not just when and how a specific ... translated into real-world dominance of one population over another. ... forced bacteria to compete in a head-to-head contest for ...
... St. Jude Children's Research Hospital have announced that a ... antigenic variant of the avian influenza virus H5N1 may ... based on this model might therefore be suitable for ... a new vaccine could be developed specifically against the ...
Cached Biology News:A new look at the state of the oceans 2A new look at the state of the oceans 3Ready, set, mutate?and may the best microbe win 2Ready, set, mutate?and may the best microbe win 3Scientists to employ Arctic ice and polar bears to protect diversity of world's crops 2
(Date:7/29/2015)... 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) announced ... be released on Thursday, August 13, 2015, before the ... management will host a conference call to discuss the ... release outlining the financial results and business update will ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and reference ...
(Date:7/29/2015)... ... July 29, 2015 , ... Finding gooey or crusty material in the ... there are a considerable number of terms in popular use to describe it, ophthalmologists ... a mixture of mucus, blood cells, skin cells and dust, but until now there ...
(Date:7/29/2015)... , ... July 29, 2015 , ... ... the company is making good progress in evaluating the full range of capabilities ... stem cells. Adult tissue stem cells perform the day-to-day renewal and repair of ...
(Date:7/28/2015)... VILLAGE, Nev. , July 28, 2015  PDL ... ) today announced that the Company will release its ... June 30, 2015, on Wednesday, August 5, 2015, after ... and webcast that day at 4:30 p.m. Eastern Time ... to the call will be available via the webcast ...
Breaking Biology Technology:Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 4PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2
... where scientists and engineers assemble spacecraft, have joined ... unlikely places where scientists have discovered ultra-hardy organisms ... uncovered in a recent NASA study have never ... Kasthuri Venkateswaran, who led the study conducted at ...
... a method for culturing mammalian neurons in chambers not much ... lifespan of the neurons at very low densities, an essential ... behavior of individual brain cells. , The technique is described ... Chemistry Lab on a Chip. , This finding will ...
... casting, splinting and bracing technology, ST. ... Technologies,Inc. of St. Paul, Minn., and Product ... to announce the launch of Exos Corporation, ... commercialize innovative orthopedic,support devices. Exos will ...
Cached Biology Technology:NASA study will help stop stowaways to Mars 2Microfluidic chambers advance the science of growing neurons 2Microfluidic chambers advance the science of growing neurons 3Enova Medical Launches Exos Corporation 2
Anti-Human Factor XI Purified (Polyclonal) (sheep IgG)...
Formulation: 10mM PBS/500 mM NaCl, 0.09% NaN3, pH 7.2...
Rad51B...
Goat polyclonal to Dysadherin ( Abpromise for all tested applications). entrezGeneID: 53827...
Biology Products: